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Since Liraglutide, a fatty acid modified glucagon like peptide -1 (GLP1) analog, is still administered parenterally, this work aims at designing and optimizating Liraglutide encapsulated in polymeric nanoparticles for oral administration implementing Quality by Design (QbD) concept from the early stage of development. Rish assessmnet based study was successfully conducted followed by selecting the crtical process parameters (CPPs) and crirtical material attributes (CMAs) with the highest risk to be further investigated applying screening design of experiment (DOE). Plackett Burman DOE was sucessfully implemented to understand and evaluate the effect of CPPs and CMAs on the size, encapsulation effeciency, polydisperisity index and zeta potential of Liraglutide loaded polymeric NPs. The design space was established and the optimized formula was prepared and examined for physiochemical properties, compatibility, structural stability and in vitro relesae behaviour. This work presents the potential of implementing the QbD methodology when designing such a complex system to ensure high quality of the final product.
